SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.5% – Should You Sell?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) traded down 8.5% during mid-day trading on Tuesday . The company traded as low as $4.96 and last traded at $5.0150. 4,021,622 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 8,579,551 shares. The stock had previously closed at $5.48.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SLS. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Price Performance

The stock’s 50 day simple moving average is $4.51 and its two-hundred day simple moving average is $2.97. The firm has a market cap of $739.83 million, a P/E ratio of -20.91 and a beta of 2.18.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Thursday, March 19th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. Equities research analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.

Institutional Trading of SELLAS Life Sciences Group

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in SELLAS Life Sciences Group by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock worth $11,012,000 after purchasing an additional 185,106 shares during the last quarter. Anson Funds Management LP grew its holdings in shares of SELLAS Life Sciences Group by 2,093.8% during the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after buying an additional 5,757,938 shares during the last quarter. Geode Capital Management LLC grew its position in SELLAS Life Sciences Group by 35.9% during the 4th quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock worth $11,604,000 after purchasing an additional 812,953 shares during the period. Marshall Wace LLP raised its stake in shares of SELLAS Life Sciences Group by 23,550.0% during the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after buying an additional 2,704,007 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock worth $8,249,000 after buying an additional 827,257 shares during the last quarter. 17.38% of the stock is currently owned by institutional investors and hedge funds.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.